Nivolumab vs Tofacitinib

## Nivolumab vs Tofacitinib: Overview

This comparison examines the pharmacological differences between **Nivolumab** and **Tofacitinib**.

## Mechanism of Action

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

**Tofacitinib**: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

## Pharmacokinetics

**Half-life**: Nivolumab — 27 days; Tofacitinib — 3.2 hours.

## Chemical Properties

**Molecular Formula**: Nivolumab — N/A; Tofacitinib — C16H20N6O.

**Molecular Weight**: Nivolumab — N/A; Tofacitinib — 312.3700 g/mol.

**Type**: Nivolumab — Antibody; Tofacitinib — Small molecule.